APVO vs ARTL

Aptevo Therapeutics Inc. vs Artelo Biosciences, Inc. — Valuation Comparison 2026

APVO

Pharmaceutical Preparations
Aptevo Therapeutics Inc.
Quality
4.2
out of 10
Value Trap
24
SAFE
Price
$4.91
Last close
Models
6/13
Active
VS

ARTL

Pharmaceutical Preparations
Artelo Biosciences, Inc.
Quality
3.9
out of 10
Value Trap
12
SAFE
Price
$1.40
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType APVO Fair ValueAPVO Upside ARTL Fair ValueARTL Upside
Bayesian DCF Intrinsic $6.09 +24.1% $2.59 +84.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.36 -92.6% $0.27 -92.1%
Dynamic NAV Asset-Based $3.99 +184.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for APVO vs ARTL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

APVO vs ARTL — Which Stock Is More Undervalued?

APVO scores higher with a 4.2/10 quality rating vs ARTL's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aptevo Therapeutics Inc. (APVO) and Artelo Biosciences, Inc. (ARTL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

APVO currently trades at $4.91 with a QOC of 4.2/10, while ARTL trades at $1.40 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).